Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Hematologic Neoplasms 9Myeloproliferative Disorders 8Multiple Myeloma 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia, Lymphocytic, Chronic, B-Cell 8Hodgkin Disease 7Lymphoma, Non-Hodgkin 6Graft vs Host Disease 6Waldenstrom Macroglobulinemia 5Lymphoma 5Burkitt Lymphoma 5Recurrence 4Primary Myelofibrosis 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Lymphoma, Mantle-Cell 4Leukemia, Prolymphocytic 4Leukemia, Myelomonocytic, Chronic 4Skin Neoplasms 3Sarcoma 3Rhabdomyosarcoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Biphenotypic, Acute 3Leukemia 3Bronchiolitis Obliterans Syndrome 3

Interventions

AZD 6244 12trametinib 4mirdametinib 2fludarabine 2Lasers, Solid-State 2Inhalation 2Deoxycholic Acid 2Acetylcysteine 2thymoglobulin 1talimogene laherparepvec 1omipalisib 1lorlatinib 1fludarabine phosphate 1encorafenib 1dabrafenib 1cabozantinib 1binimetinib 1abemaciclib 1Waiting Lists 1Vincristine 1Specimen Handling 1Sirolimus 1Rituximab 1Radiation 1Polidocanol 1N-monoacetylcystine 1Melphalan 1Magnetic Resonance Spectroscopy 1Lovastatin 1Liquid Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × Sirolimus × 1 year × Clear all
NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
21 enrolled 12 charts
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡